Expertise in
26
conditions

Dr. Thomas J. Galloway

Radiation Oncology | Otolaryngology
Fox Chase Cancer Center
333 Cottman Avenue, 
Philadelphia, PA 
Expertise in
26
conditions
Fox Chase Cancer Center
333 Cottman Avenue, 
Philadelphia, PA 

Overview

Thomas Galloway is an Otolaryngologist and a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Galloway is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Adenoid Cystic Carcinoma, Tongue Cancer, and Throat Cancer.

Dr. Galloway is board certified in American Board Of Radiology - Radiation Oncology. He is actively involved in clinical research, co-authoring 92 peer reviewed articles and participating in 7 clinical trials.

Graduate Institution

BS, Chemistry, University Of Florida, Gainesville, FL, 2001

Specialties

Radiation Oncology
Otolaryngology

Licenses

Radiology in FL

Board Certifications

American Board Of Radiology - Radiation Oncology

Hospital Affiliations

Hospital Of Univ Of Pennsylvania
Temple University Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Fox Chase Cancer Center
333 Cottman Avenue, Philadelphia, PA 19111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Completed
Publish Date: March 06, 2025
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Lapatinib
Study Phase: Phase 2
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
View 6 Less Clinical Trials

92 Total Publications

Systemic Treatment of Thyroid Cancer: ASCO Guideline.
Systemic Treatment of Thyroid Cancer: ASCO Guideline.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 01, 2026
Similar Doctors
Expertise in
41
conditions
Dr. Joseph M. Curry
Otolaryngology | General Surgery
Expertise in
41
conditions
Dr. Joseph M. Curry
Otolaryngology | General Surgery
Referral may be required

Jefferson Otolaryngology (ENT) - Honickman Center

1101 Chestnut Street, Floor 16, 
Philadelphia, PA 
 (3.7 miles away)
215-955-6760
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph Curry is an Otolaryngologist and a General Surgeon practicing medicine in Philadelphia, Pennsylvania. Dr. Curry is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Salivary Duct Stones, Throat Cancer, Laryngectomy, and Gastrostomy. Dr. Curry is board certified in Otolaryngology. Dr. Curry is currently accepting new patients.

Expertise in
32
conditions
Dr. David M. Cognetti
Otolaryngology
Expertise in
32
conditions
Dr. David M. Cognetti
Otolaryngology
Referral may be required

Jefferson Otolaryngology (ENT) - Honickman Center

1101 Chestnut Street, Floor 16, 
Philadelphia, PA 
 (3.7 miles away)
215-955-6760
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Cognetti is an Otolaryngologist practicing medicine in Philadelphia, Pennsylvania. Dr. Cognetti is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Salivary Duct Stones, Sialadenitis, Laryngectomy, and Gastrostomy. Dr. Cognetti is board certified in Otolaryngology - Head & Neck Surgery and Otolaryngology. Dr. Cognetti is currently accepting new patients.

Expertise in
26
conditions
Dr. Nithin D. Adappa
Otolaryngology
Expertise in
26
conditions
Dr. Nithin D. Adappa
Otolaryngology
Referral may be required

Penn Pituitary Center

3400 Civic Center Boulevard, South Pavilion, 2nd Floor, 
Philadelphia, PA 
 (4.6 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nithin Adappa is an Otolaryngologist practicing medicine in Philadelphia, Pennsylvania. Dr. Adappa is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Cerebrospinal Fluid Leak, Sinusitis, Sinus Cancer, Endoscopy, and Endoscopic Transnasal Transsphenoidal Surgery. Dr. Adappa is board certified in Otolaryngology, 2011. Dr. Adappa is currently accepting new patients.

Frequently Asked Questions about Dr. Thomas J. Galloway

How do I make an appointment with Dr. Thomas J. Galloway?

You can book an appointment with Dr. Thomas J. Galloway by calling their office at 888-369-2427. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Thomas J. Galloway a top-rated expert for Laryngeal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thomas J. Galloway is classified as an Distinguished expert for Laryngeal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thomas J. Galloway specialize in?

While Dr. Thomas J. Galloway is a Radiation Oncology, they have specific expertise in Laryngeal Cancer, Adenoid Cystic Carcinoma, and Tongue Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Thomas J. Galloway participate in research or clinical trials?

Yes. Dr. Thomas J. Galloway has published 92 articles and abstracts on conditions like Laryngeal Cancer. You can view a list of Dr. Thomas J. Galloway's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Thomas J. Galloway accept my insurance?

Dr. Thomas J. Galloway accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 888-369-2427 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Galloway's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile